Sun Pharma to Acquire Checkpoint Therapeutics
Portfolio Pulse from
Sun Pharma is set to acquire Checkpoint Therapeutics, adding the FDA-approved anti-PD-L1 treatment UNLOXCYT™ to its portfolio. The acquisition involves an upfront cash payment of $4.10 per share, totaling up to $355 million, with an additional contingent value right of $0.70 per share. The deal is pending approval from Checkpoint's stockholders and other conditions.
March 10, 2025 | 2:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Checkpoint Therapeutics is being acquired by Sun Pharma for $4.10 per share, with a potential additional $0.70 per share contingent on milestone achievement. This acquisition will add Checkpoint's FDA-approved treatment to Sun Pharma's portfolio.
The acquisition by Sun Pharma is likely to positively impact Checkpoint's stock price in the short term due to the premium offered over current market prices and the strategic value of the FDA-approved treatment being added to Sun Pharma's portfolio.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100